Taking the risk into consideration, we used TipRanks’ database to find compelling penny stocks with bargain price tags. In addition, the $4 average price target brings the upside potential to 304%. (See AZRX stock analysis on TipRanks) ProQR (PRQR) ProQR is a biotechnology company focused on treatments for congenital progressive blindness. QR-421 is in Phase 1/2 studies, with an aim of restoring lost vision or preventing the loss in the first place. In line with his upbeat outlook, Wolleben puts a $20 price target on the stock, implying a 384% one-year upside, along with an Outperform (i.e.

Source: The North Africa Journal January 22, 2021 14:22 UTC